Search
Diza Pharmaceutical Announces FDA Fast Track Designation for DZD8586
2025-08-06 /
Read about 0 minute
Author：小编
Diza Pharmaceutical's pioneering, first-in-class LYN/BTK dual-target inhibitor DZD8586 has recently been granted FDA Fast Track Designation. This designation is for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in patients who have undergone at least two prior lines of therapy. DZD8586 uniquely targets both BTK-dependent and independent BCR signaling pathways, offering a promising new therapeutic avenue for these patients.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
